WHO, Immunization, Vaccines and Biologicals, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
Vaccine. 2017 Oct 13;35(43):5753-5755. doi: 10.1016/j.vaccine.2017.05.069. Epub 2017 Jun 5.
This article presents the World Health Organization's (WHO) recommendations on the use of human papillomavirus (HPV) vaccines excerpted from the WHO position paper on Human papillomavirus vaccines: WHO position paper, May 2017, published in the Weekly Epidemiological Record [1]. This position paper replaces the 2014 WHO position paper on HPV vaccines [2]. The position paper focuses primarily on the prevention of cervical cancer, but also considers the broader spectrum of cancers and other diseases preventable by HPV vaccination. It incorporates recent developments concerning HPV vaccines, including the licensure of a nonavalent (9-valent) vaccine and recent data on vaccine effectiveness, and provides guidance on the choice of vaccine. New recommendations are proposed regarding vaccination strategies targeting girls only or both girls and boys, and vaccination of multiple birth cohorts [3]. Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation table. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. Recommendations on the use of HPV vaccines were discussed by SAGE in October 2016; evidence presented at these meetings can be accessed at: www.who.int/immunization/sage/meetings/2016/october/presentations_background_docs/en/.
本文介绍了世界卫生组织（WHO）关于人乳头瘤病毒（HPV）疫苗使用的建议，这些建议摘自《WHO关于人乳头瘤病毒疫苗的立场文件：2017年5月WHO立场文件》，该文件发表于《疫情周报》[1]。本立场文件取代了WHO 2014年关于HPV疫苗的立场文件[2]。该立场文件主要关注宫颈癌的预防，但也考虑了HPV疫苗可预防的更广泛的癌症和其他疾病。它纳入了HPV疫苗的最新进展，包括九价疫苗的获批情况以及疫苗有效性的最新数据，并就疫苗选择提供了指导。针对仅针对女孩或同时针对女孩和男孩的疫苗接种策略以及多出生队列的疫苗接种提出了新的建议[3]。本文的脚注提供了一些核心参考文献，包括评估科学证据质量的分级表以及证据与建议表的参考文献。根据其在卫生政策事项上为会员国提供指导的任务规定，WHO发布了一系列定期更新的立场文件，内容涉及对具有国际公共卫生影响的疾病的疫苗及疫苗组合。这些文件主要关注疫苗在大规模免疫规划中的使用；它们总结了疾病和疫苗的基本背景信息，并以WHO在全球范围内使用疫苗的当前立场作为结论。免疫战略咨询专家组（SAGE）于2016年10月讨论了HPV疫苗使用的建议；这些会议上展示的证据可在以下网址查阅：www.who.int/immunization/sage/meetings/2016/october/presentations_background_docs/en/ 。
